Wednesday, February 22, 2012 12:15:19 PM
WHAT??? NO GLOOM AND DOOM??? Perfectly said Whopperman...
I haven't even really bothered checking in on this. With the calls for drops, you know emotion would take over if no pr's or 8-Ks were released immediately for the emotional masses. This company doesn't operate that way though. However, no one likes to see their investment value drop and any one of us would be lying to say it doesn't tick you off. The emotional sell-off is understandable if you invest on emotion. But no one should ever invest on emotion - unless it's a P&D and you can see the emotional pattern - P&D's are all about who gets spooked and who calls the top. ATRN should be seen as neither. GLTA.
I haven't even really bothered checking in on this. With the calls for drops, you know emotion would take over if no pr's or 8-Ks were released immediately for the emotional masses. This company doesn't operate that way though. However, no one likes to see their investment value drop and any one of us would be lying to say it doesn't tick you off. The emotional sell-off is understandable if you invest on emotion. But no one should ever invest on emotion - unless it's a P&D and you can see the emotional pattern - P&D's are all about who gets spooked and who calls the top. ATRN should be seen as neither. GLTA.
Warren Buffett spent eight years working with it before discarding it as worthless. What investment strategy is that? Technical analysis - aka CHARTS
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
